ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Zhejiang Doer Biologics Announces Phase I Trial Of Dr10624
News Feed
course image
  • Date not available
  • Admin
  • News Article

Zhejiang Doer Biologics Announces Phase I Trial of DR10624

Zhejiang Doer Biologics has announced the successful dosing completion of the initial participant in their Phase Ib 12-week Multiple-Ascending Dose (MAD) trial for DR10624. 

This first-in-class (FIC) compound functions as a tri-specific agonist, targeting Glucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR), and Fibroblast growth factor 21 receptor (FGF21R). The study's primary focus is evaluating DR10624's potential for treating obesity and hypertriglyceridemia in New Zealand.

The Phase I MAD (Multiple Ascending Dose) study is a clinical trial to investigate the safety, tolerability, pharmacokinetics (how the drug moves within the body), and pharmacodynamics (how the drug interacts with the body) of DR10624.

DR10624 is a novel FIC tri-specific biotherapeutic designed to selectively activate three distinct receptors: GLP-1R (Glucagon-Like Peptide-1 Receptor), GCGR (Glucagon Receptor), and FGF21R (Fibroblast Growth Factor 21 Receptor). The proprietary MultipleBody® platform technology developed by Doer Bio enables to exhibit balanced activity for metabolic diseases.

In preclinical investigations, DR10624 consistently exhibited favourable outcomes, including reductions in body weight, improved glucose levels, enhanced metabolic function, and better liver functionality.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form